Analysts predict significant growth potential for penny stocks SKYE and PYPD

From Yahoo Finance: 2025-06-22 06:15:00

In the stock market, big names dominate the headlines, but the real gems may be hidden among penny stocks trading for $5 or less. These under-the-radar opportunities can explode with growth when the right catalyst strikes, offering significant upside potential.

Skye Bioscience (SKYE) is a biopharmaceutical company focusing on innovative treatments for metabolic disorders like obesity. With a global anti-obesity drug market projected to reach $104.9 billion by 2035, SKYE’s lead candidate, nimacimab, is poised to target weight loss through a novel approach. Positive results from preclinical and Phase 1 testing show promise for its future.

PolyPid (PYPD) is a clinical-stage biopharmaceutical company revolutionizing post-operative care with its drug delivery platform, PLEX. The recent success of its lead product candidate, D-PLEX100, in preventing surgical site infections following abdominal colorectal procedures has positioned the company for FDA approval and potential market expansion. Analysts are bullish on its growth potential.

Both SKYE and PYPD are attracting attention from Wall Street analysts, with significant upside potential. SKYE is forecasted to surge by nearly 590%, while PYPD could see a one-year gain of 174%. The consensus ratings for both stocks are Strong Buy, reflecting optimism in their future prospects.



Read more at Yahoo Finance: Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks